Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
1Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan, 1500 E. Medical Center Drive, SPC 5848, Med Inn C349, Ann Arbor, MI, 48103, USA.
Opinion Statement:
EGFR tyrosine kinase inhibitors (TKI) should always be considered when treating advanced/metastatic non-small cell lung cancer (NSCLC) with atypical EGFR mutations. The first choice of TKI depends on the specific mutation(s) present and its effect on structure and function of the EGFR protein. Afatinib is the only EGFR TKI currently FDA approved for atypical EGFR mutations and has the strongest data to support its use in PACC mutations, a subgroup of atypical EGFR mutations which includes G719X and S7681. Dacomitinib may also be an option for these mutations given similar efficacy to afatinib. In contrast, for classical-like mutations such as L861Q, osimertinib should be considered the first choice given that their behavior mimics that of the classical mutations exon 19 deletion and L858R. Osimertinib should also be utilized in the setting of a concurrent T790M mutation. Superior CNS penetrance and well managed toxicity profile may also be reasons to consider osimertinib. Given that the choice of TKI may depend on the specific mutation, it is crucial that every patient diagnosed with NSCLC undergo comprehensive sequencing to identify these mutations.
Insights
Choosing the right EGFR tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) depends on specific mutations. Comprehensive genetic sequencing is crucial for personalized treatment selection.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced/metastatic non-small cell lung cancer (NSCLC) treatment involves EGFR tyrosine kinase inhibitors (TKIs).
- Atypical EGFR mutations require specific TKI selection for optimal efficacy.
- EGFR protein structure and function are influenced by various mutations.
Purpose of the Study:
- To guide the selection of appropriate EGFR TKIs for NSCLC patients with atypical EGFR mutations.
- To highlight the role of specific TKIs based on mutation type and clinical data.
- To emphasize the importance of comprehensive genomic profiling in NSCLC.
Main Methods:
- Review of current FDA-approved EGFR TKIs and their indications.
- Analysis of clinical data supporting TKI use in specific atypical EGFR mutation subgroups.
- Comparison of TKI efficacy, CNS penetration, and toxicity profiles.
Main Results:
- Afatinib is FDA-approved for atypical EGFR mutations, particularly PACC mutations (G719X, S768I), with strong supporting data.
- Dacomitinib shows comparable efficacy to afatinib for PACC mutations.
- Osimertinib is recommended for classical-like mutations (L861Q) and concurrent T790M mutations, offering superior CNS penetration and manageable toxicity.
Conclusions:
- TKI selection for NSCLC with atypical EGFR mutations must be tailored to the specific mutation profile.
- Comprehensive sequencing is essential for identifying mutations and guiding personalized TKI therapy.
- Afatinib, dacomitinib, and osimertinib represent key therapeutic options depending on the identified EGFR mutation status.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Tumor Immunotherapy